Johnson & Johnson Advances IBD Therapy JNJ-4804 Despite Phase 2b Trial Miss
Johnson & Johnson’s experimental IBD therapy JNJ-4804, combining Tremfya and Simponi, failed to meet its primary endpoint in Phase 2b trials for ulcer...
Johnson & Johnson’s experimental IBD therapy JNJ-4804, combining Tremfya and Simponi, failed to meet its primary endpoint in Phase 2b trials for ulcer...
Condé Nast closed Self magazine, a women’s health publication known for its practical coverage of chronic illnesses. Readers and advocates mourn the l...
Jamie Harris spent years dismissing her digestive symptoms as diet-related before a Crohn’s disease diagnosis in her 20s. Her journey highlights the d...